ライフサイエンスコーパス: tumor weight

1 tively correlated with iTreg frequencies and tumor weight.

2 aring the tracer uptake and correlation with tumor weight.

3 iated with PFS after adjusting for stage and tumor weight.

4 lymph sinuses is correlated with the primary tumor weight.

5 in vivo; 4.7-T MR imaging was used to derive tumor weight.

6 AM-1 transfectants correlate positively with tumor weight.

7 with a 90% inhibition of tumor incidence and tumor weight.

8 ffinity for CR3 caused a 57-90% reduction in tumor weight.

9 s tamoxifen exhibited reduced tumor area and tumor weight.

10 is treatment compared with that of controls (tumor weights 170 +/- 10 and 240 +/- 50 mg, respectively

11 g/kg(-1)/h(-1) 1400W compared with controls (tumor weights 340 +/- 50 and 580 +/- 90 mg, respectively

12 )/h(-1) resulted in significant reduction in tumor weight (357 +/- 46 and 466 +/- 70 mg, respectively

13 ition of tumor volume (62.3%; P < 0.001) and tumor weight (61.1%; P < 0.01) was observed after 4 week

14 n reduced prostate weights, tumor areas, and tumor weight (62%, P<0.001), whereas finasteride reduced

15 ssion of ZIP4 not only increased the primary tumor weight (7.2-fold), it also increased the peritonea

16 se in tumor volume and by a 71% reduction in tumor weight after 7 weeks as compared with the control

17 e chlorin(e6) produced a smaller decrease in tumor weight and a smaller extension of survival, neithe

18 sonance (MR) imaging was performed to derive tumor weight and analyze morphology.

19 After imaging, excised tumor weight and biodistribution were assessed.

20 he effect of co-treatment of DOX and iRGD on tumor weight and cell death.

21 r, to tumor-bearing mice decreased xenograft tumor weight and inhibited progression to invasion.

22 Tumor weight and proliferation (Ki-67 expression) were d

23 phosphorylation, advanced pathologic stage, tumor weight and size, and prognosis of ccRCC patients.

24 l treatment in vivo) significantly decreased tumor weight and splenomegaly in tumor-bearing mice with

25 In contrast, primary tumor weight and vascular density were unchanged between

26 yed tumor growth by 3 weeks and reduced both tumor weight and volume by 90%.

27 The significant reduction (P < 0.05) in tumor weight and volume observed between the PDT + TNP-4

28 gated after 2 weeks of treatment in terms of tumor weights and tumor burden in vivo.

29 ease in final tumor volume, 54% reduction in tumor weight, and the extension of tumor-doubling time f

30 ber of tumors/mouse, and reduced the average tumor weight/animal.

31 y reduced tumor incidence, tumor number, and tumor weight at both doses.

32 tumor volume and 42% (P = 0.012) decrease in tumor weight at the end of the experiment without any ad

33 pressing tumors grew 3- to 4-fold slower and tumor weights at day 35 were 3- to 6-fold less than the

34 or 18%, respectively, whereas tomato reduced tumor weight by 34% (P<0.05).

35 ion of PC3-MM2 prostate cancer cells reduced tumor weight by 37% in mice treated with PEG-IFN-alpha-2

36 < 0.05) inhibited tumor volume by 62.9% and tumor weight by 47.8%.

37 reducing tumor volume by 59.9% to 79.2% and tumor weight by 61.0% to 76.9% (all P < 0.05).

38 inished tumor volume by 80.9% (P < 0.01) and tumor weight by 82.0% (P < 0.01).

39 5 reduced circulating PSA levels by 99% and tumor weight by 85% at a dose just below its MTD.

40 ft studies, 27 reduced PSA levels by 95% and tumor weight by 87% at a dose below its MTD.

41 Broccoli decreased tumor weights by 42% (P<0.01) whereas the 10:10 combinat

42 ated with genistin and SPC had reduced final tumor weights by 56% (P < 0.05) and 52% (P < 0.05), resp

43 4 nmol/g of the diet insignificantly reduced tumor weights by 7% or 18%, respectively, whereas tomato

44 n microvessel density and a 50% reduction in tumor weight compared with treatment with a nonspecific

45 -11, and 5FU all resulted in decreased final tumor weights compared with vehicle-treated controls (P<

46 ron emission tomography/computed tomography, tumor weight determinations, and histopathology.

47 elated with proliferation, invasiveness, and tumor weight (Fisher Exact Test or Spearman Correlation,

48 nd a statistically significant difference in tumor weight for mice treated with DOX and iRGD compared

49 Tumor weights from mice administered saline or Tempol al

50 b expression were positively correlated with tumor weight; heavier tumors, in turn, were characterize

51 after 21 days showed a reduction in prostate tumor weight in all groups compared with controls, which

52 itaxel treatment shows a greater decrease in tumor weight in both xenograft models than mitotane.

53 sulted in a greater than 4-fold reduction of tumor weight in comparison to controls at day 14 (100 +/

54 med free gemcitabine with a 62% reduction in tumor weight in pancreatic xenografts.

55 treated mice (P=0.048), and the mean mammary tumor weight in the MIS-treated group was significantly

56 er, and tumor response end points were total tumor weight in the short term and survival in the long

57 The EE mice showed significantly reduced tumor weights in both subcutaneous (53%) and orthotopic

58 The loss in tumor weights in response to CLG-shAnxA2 was associated

59 model, 24 compounds elicited percentages of tumor weight inhibitions (TWI) ranging from 50% to 99%.

60 wed a marked increase in the mean pancreatic tumor weight (low dose (100 mg/m(3) total suspended part

61 with CPT-11, significant decrements in final tumor weights occurred compared with monotherapy with th

62 ered Tempol followed by 6OHDA had an average tumor weight of 0.7 +/- 0.3 g.

63 IPE1 significantly diminished the growth and tumor weight of murine liver cancer homografts.

64 On days 21 and 28 the net tumor weight of the AL-3789-treated animals was 40% to 3

65 on accelerated tumor formation and increased tumor weight (P<.01), whereas mPGES-1 knockdown delayed

66 nockdown delayed tumor formation and reduced tumor weight (P<.01).

67 UL39 with G207 resulted in a 66% decrease in tumor weights (P < 0.0001) and a 65% reduction in tumor

68 level as orchidectomy, significantly reduced tumor weights (P < 0.05), significantly lowered serum le

69 r the combination group (17% of control mean tumor weight; P < 0.001; 7 of 13 clinical complete respo

70 el density, and the corresponding hemoglobin:tumor weight ratio was increased 2-fold relative to L/M

71 GH-RH antagonist also significantly reduced tumor weight, serum levels of GH and IGF-I, liver concen

72 kg and CPT-11 at 50 mg/kg) resulted in final tumor weights similar to those achieved after administra

73 Cox regression analysis, age, disease stage, tumor weight, somatic TP53 mutations, and Ki-67 LI were

74 e and paclitaxel had significantly decreased tumor weight than the control, paclitaxel-alone, or itra

75 We show that tumor weight, volume, and vessel density are all reduced

76 injection of tumor cells, a 75% reduction in tumor weight was observed when wortmannin treatments wer

77 e was reduced by 40.0% (P < 0.05), and their tumor weight was reduced by 42.8% (P < 0.01) after 4 wee

78 etastatic nodules (105 versus 68 tumors) and tumor weight were significantly lower than those in the

79 Tumor weights were 43% less (P < .05) than controls (5.9

80 fter the first injection, endostatin-treated tumor weights were 51% of controls (P < 0.01).

81 Tumor weights were compared and sterol composition, hepa

82 Intraocular tumor weights were determined on days 10, 14, 21, and 28

83 Liver tumor weights were reduced from 0.37 to 0.10 gram (P = 0

84 hibited both tumor take rate and final liver tumor weight when compared with treatment with control s

85 as the original study reported a decrease in tumor weight when DOX was coadministered with iRGD.

86 decreased both tumor cell proliferation and tumor weight with no effect on rate of apoptosis.

87 ontrols without rupture according to age and tumor weight (within 6 months and 50 g, respectively).